Demonstrated in vivo, SYK interacts with and activates FLT3 directly, making FLT3-ITD more sensitive to SYK inhibition, further supporting the screening of FLT3-ITD as an important determinant of prognosis in AML patients [159]. Here, SYK is linked to acute myeloid leukemia.